James Avery Artisan Jewelry Opens New Store at Westover Marketplace
KERRVILLE, Texas, June 1, 2024 /PRNewswire/ — James Avery Artisan Jewelry, a family-owned jewelry retailer based in Texas, is excited to announce the opening of its new store at Westover Marketplace in San Antonio. The new store is located at 8219 State Highway 151, Suite 128, San Antonio, TX
Boehringer Ingelheim’s COPD and asthma inhalers are now available for $35 a month for eligible patients
Boehringer’s first-of-its-kind program automatically reduces the costs of its COPD and asthma inhalers at the pharmacy counter for vast majority of eligible patientsProgram provides predictable, affordable and consistent costs for as many patients as possible, including uninsured patients and
TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting
Poster presentation features the interim data from an ongoing Phase 1b clinical trial of TU2218 plus Keytruda combination therapy in patients with advanced solid tumorsA 40% overall response rate (ORR) and 100% disease control rate (DCR) were achieved in high-dose cohort (195 mg/day)TU2218 was well
CMA reflects on National Indigenous History Month
OTTAWA, ON, June 1, 2024 /CNW/ – The Canadian Medical Association (CMA) is pleased to join people across the country in recognizing National Indigenous History Month. As we reflect on the rich history, resilience, diverse cultures and achievements of First Nations, Inuit and Métis Peoples, we
BALEAF & SOJOS to host “Summer it up” summer fashion extravaganza!
NEW YORK, June 1, 2024 /PRNewswire/ — Leading fashion brands baleaf and SOJOS are teaming up to present a spectacular summer fashion event, Summer it up set to take place this June in Chicago. More than just a fashion show, this event aims to empower individuals to define their unique style f
Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024
Zanidatamab demonstrated a median overall survival (OS) of 15.5 months in patients with centrally confirmed immunohistochemistry (IHC) 2+ or 3+ and a median OS of 18.1 months in patients with IHC 3+ tumors With approximately two years of median follow-up, as of July 28, 2023, median duration of res
/R E M I N D E R — Media Advisory – Prime Minister’s itinerary for Saturday, June 1, 2024/
OTTAWA, ON, May 31, 2024 /CNW/ – Note: All times local National Capital Region, Canada No public events scheduled This document is also available at https://pm.gc.ca SOURCE Prime Minister’s Office
Duke-NUS’ largest graduating cohort celebrates diverse pathways to medicine
The largest graduating class in Duke-NUS’ history saw 90 graduates, including the first-ever Master of International Translational Medicine cohort, receive their degreesCollectively, this cohort published 99 academic publications, underscoring Duke-NUS’ role as a leader in innovation and
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Benefit: PFS Hazard Ratio of 0.46 For Subset of Patients Previously Receiving 3rd Generation EGFR-TKI: PFS Hazard Ratio of 0.48 5.6% Treatment Discontinuation of Ivonescimab du
ZEEKR Announces May 2024 Delivery Update
HANGZHOU, China, June 1, 2024 /PRNewswire/ — ZEEKR Intelligent Technology Holding Limited (“ZEEKR” or the “Company”) (NYSE: ZK), a fast-growing intelligent battery electric vehicle (“BEV”) technology company, today announced its delivery results for May 202
